Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose.
|ClinicalTrials.gov Identifier: NCT01230463|
Recruitment Status : Unknown
Verified October 2010 by University of Calgary.
Recruitment status was: Recruiting
First Posted : October 29, 2010
Last Update Posted : October 29, 2010
|Condition or disease||Intervention/treatment||Phase|
|Pain Pain, Postoperative||Drug: Ketorolac Tromethamine||Not Applicable|
Opioids have traditionally been the cornerstone of acute postoperative pain management. Problematic side effects such as nausea, vomiting, ileus, urinary retention, excess sedation, and respiratory depression are significant disadvantages with the use of opioids. Alternative treatments have been sought. The concept of adding a nonsedating non opioid analgesic agent is appealing and has been validated by previous studies. Nonsteroidal anti-inflammatory drugs (NSAID) are nonsedating and combine analgesic and anti-inflammatory properties ideal for pain after surgery.
Ketorolac is a potent intravenous nonsteroidal anti-inflammatory drug (NSAID), and a non selective cyclooxygenase inhibitor which mediates pain, inflammation and fever. It has been evaluated and used for treatment of moderate to severe pain including postoperative pain. Although intravenous route is not approved by Health Canada, its use is supported in medical literature and clinical practice.
Previous studies have demonstrated the effectiveness of standard 30 mg intravenous ketorolac as an adjunct to opioids for postoperative pain relief. Standard parenteral dose recommended by manufacturer for healthy non elderly population is 30 mg based on a number clinical trials.
Alberta Health Services (AHS) Pharmacy formulary has approved the intravenous use of ketorolac in the dosage range of 10-30 mg depending the patient's weight and medical comorbidities.
NSAIDs, including ketorolac, have an analgesic ceiling effect in which higher doses do not provide any additional pain relief but may increase the likelihood of side effects. Single dose IM ketorolac have been studied in the past showing no difference in analgesia with the 30 and 90 mg dose. Because of risk of drug toxicity and unwanted side effects, patients should be given the lowest effective ketorolac dose. Low dose ketorolac was studied in the adolescents undergoing spine surgery and showed that dose of 0.2mg/kg (11mg) provides supplemental analgesia postoperatively. However, there were no previous studies found on review of the literature using medline search that look at parallel comparison between intraoperative doses of ketorolac in terms of efficacy and safety profile.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Intraoperative Ketorolac Dose of 15 mg Versus the Standard 30 mg on Early Postoperative Pain After Spine Surgery: A Randomised, Blinded, Non-Inferiority Trial|
|Study Start Date :||September 2010|
|Estimated Primary Completion Date :||September 2011|
|Estimated Study Completion Date :||September 2011|
|Active Comparator: 15 mg ketorolac IV||
Drug: Ketorolac Tromethamine
15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
Other Name: Toradol
|Active Comparator: 30 mg ketorolac IV||
Drug: Ketorolac Tromethamine
30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
Other Name: Toradol
- Visual Analog Score [ Time Frame: Four hours after surgery ]To show the non-inferiority of 15 mg intraoperative dose of ketorolac as compared to the standard 30 mg ketorolac by looking at the VAS scores 4 hours after an adult spine surgery. Minimum clinically significant decrease in VAS pain score is 18 mm.
- Morphine Usage After Surgery [ Time Frame: 8 hours and 24 hours after surgery ]A 10 mg decrease in morphine use in 24 hours is considered clinically significant.
- Morphine Adverse Effects [ Time Frame: First 24 hours ]Presence of morphine-related adverse effects such as sedation, nausea, vomiting, respiratory depression, and pruritus.
- Postoperative Bleeding [ Time Frame: 24 hours after surgery ]Hemoglobin levels will be measured before surgery and 24 hours surgery.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01230463
|Contact: Cecilia Deguzman, MD||403-944-1991||Cecilia.DeGuzman@albertahealthservices.ca|
|Contact: Kevin Yee, MDemail@example.com|
|Foothills Medical Centre||Recruiting|
|Calgary, Alberta, Canada, T2N 2T9|
|Principal Investigator:||Kaylene Duttchen, MD||University of Calgary - Department of Anesthesia|
|Principal Investigator:||Melinda Davis, MD||University of Calgary - Department of Anesthesia|